News for Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics' CardiolRx shows promise in treating heart conditions. Click here to read more about CRDL stock and why it is a Strong Buy.

PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024

Here is how Cardiol Therapeutics Inc. (CRDL) and Catalent (CTLT) have performed compared to their sector so far this year.

New York-based WW International, Inc. (WW) is up over 54 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

With U.S. stock futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Hele...

Cardiol Therapeutics announces public offering of shares

Cardiol Therapeutics (CRDL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Shares of Cardiol Therapeutics Inc (CRDL) surged 8.74% in mid-day trading on Sep 9. The stock reached an intraday high of $2.00, before settling at $1.99, u

Cardiol Therapeutics' lead drug CardiolRx undergoing clinical trials for Pericarditis and Myocarditis. See why I rate CRDL stock as a strong buy.

Stocks Analysis by Joel Latham covering: Eli Lilly and Company, Pfizer Inc, Redhill Biopharma Ltd, Corbus Pharmaceuticals Holding. Read Joel Latham's latest article on Investing.com

Maryland-based biotechnology company Gain Therapeutics, Inc. (GANX) is down over 27 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

CARDIOL THERAPEUTICS INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS THREE MONTHS ENDED MARCH 31, 2024 ...

Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028.

In this piece, we will take a look at the 11 best small cap pharma stocks to invest in.

Gainers Near Intelligence, Inc. (NASDAQ: NIR) shares rose 34.1% to $0.2801 in pre-market trading after falling 42% on Wednesday. Near Intelligence recently named its General Counsel, Jay Angelo, to also serve as the company’s Chief Privacy Officer.

The massacre, stock by stock, all 1001 of them, listed right here.

Gainers Bright Green Corp. (NASDAQ: BGXX) jumped 90.5% to close at $48.08 on Wednesday. Bright Green Corporation, went public on the NASDAQ Tuesday, becoming the first U.S. plant-touching company to list on a major U.S. stock exchange.

During Friday's session, 198 companies made new 52-week lows. Key Facts About Today's 52-Week Highs And Lows: Alibaba Group Holding ...